Biogen And Sage On Plans To Build A Brain Franchise Together
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
You may also be interested in...
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption
Biogen has been granted new US patents for Tecfidera after generics already launched. It's unclear how Biogen will proceed but management could shed more light on the matter during the first quarter call.
The J.P. Morgan Healthcare Conference will be a virtual event but the industry's biggest business meeting will still lay the groundwork for the year ahead.